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Summary
    Recently novel treatment modalities has focused on targeted therapies. Tyrosine kinases represent 
a good target for cancer treatment since they are involved in transferring phosphate groups from 
ATP to tyrosine residues in specific substrate proteins transducing intracellular signals engaged 
in the many mechanisms, playing an important role in the modulation of growth factors signa-
ling that are strongly related to carcinogenesis. Deregulation of tyrosine kinases activity was also 
found in hematological malignancies, particularly overexpression of tyrosine kinases was obse-
rved in chronic myeloid leukemia or acute lymphoblastic leukemia. Herein we show that tyrosi-
ne kinase inhibitors have revolutionized hematology malignancies therapy in a very short period 
of time and they still remain one of the most interesting anticancer compounds that could give 
a hope for cure and not only long-lasting complete remission. This manuscript summarizes cur-
rent view on the first generation tyrosine kinase inhibititor – imatinib, second generation – da-
satinib, nilotinib and bosutnib as well as new generation tyrosine kinase inhibititors – ponatinib 
and danusertib in hematooncology.
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Streszczenie
    W ostatnich latach nowe strategie leczenia nowotworów opierają się głównie na terapii celowa-
nej. Kinazy tyrozynowe ze względu na to, iż przenoszą reszty fosforanowe z adenozynotrifosfora-
nu (ATP) na tyrozynę uczestnicząc w transmisji najważniejszych sygnałów międzykomórkowych 
niezbędnych w procesach wzrostowych, związanych między innymi z kancerogenezą, stanowią 
dobry cel w terapii przeciwnowotworowej. Zaburzenia w regulacji aktywności kinaz tyrozyno-
wych są często stwierdzane w rozrostowych chorobach hematologicznych, szczególnie obserwo-
wano nadekspresję kinazy tyrozynowej w przewlekłej białaczce szpikowej oraz ostrej białaczce 
limfoblastycznej. W pracy opisano znaczenie inhibitorów kinazy tyrozynowej w hematoonkolo-
gii. Leki te zrewolucjonizowały terapię przeciwbiałaczkową i są jednymi z najbardziej aktywnych 
związków terapeutycznych dających nadzieję nie tylko na osiągnięcie długotrwałej remisji, ale 
także na całkowite wyleczenie. Publikacja podsumowuje aktualną wiedzę dotyczącą imatynibu 
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Despite better understanding of the patomechanism of he-
matological malignancies and novel therapeutic strategies 
most of leukemias remains incurable. Conventional chemo-
therapy or bone marrow transplantation, only in some ca-
ses, is able to completely eliminate the disease. Moreover, 
most therapies are accompanied with adverse effects that 
could even limit patient’s survival in certain circumstan-
ces. Therefore there is a growing interest in targeted thera-
pies in recent years. These treatments are also often asso-
ciated with lower toxicity and better direct action against 
cancer-specific molecules or signaling pathways which are 
specifically deregulated in tumorigenesis [3]. It has been 
proved that tyrosine kinases (TK) represent a good target 
for cancer therapy. They are involved in the most impor-
tant mechanisms controlling cell growth and proliferation. 
They play an important role in the modulation of growth 
factor signaling which is strongly related to carcinogene-
sis, participating in various cellular processes including 
cell growth, proliferation, differentiation, and cell death. 
Tyrosine kinases are subclass of substrate protein kinases 
involved in transferring phosphate groups from ATP to ty-
rosine residues in specific substrate proteins transducting 
intracellular signals (fig. 1). Some changes caused by gene 
mutation can lead to overproduction of proteins functio-
ning as tyrosine kinases, which are responsible for proli-
feration of particular cell lines, what results in uncontrol-
led cell proliferation and resistance to apoptotic stimuli.
Deregulation of TK activity contributes to development of 
neoplastic diseases, therefore controlling of their activity 
can have a principal meaning in the treatment. Oncogenic 
TK, which are expressed in malignant tumors, inhibit apop-
tosis, alter cell adhesion and stimulate growth factor-inde-
pendent cell proliferation. It was found that oncogenic TK 
exhibit increased enzymatic activity compared with the 
proteins of normal cells [16,39,85].
ModulatIon of tyrosIne kInase actIvIty In chronIc MyeloId 
leukeMIa and acute lyMphoblastIc leukeMIa
The most common aberrantly activated TK is protein 
BCR/ABL (p210), which is a product of gene associated 
with Philadelphia chromosome. This unique chromoso-
me is generated by translocation t(9,22)(q34: q11) which 
produces aberrant TK BCR/ABL (fig. 2). This mutation is 
present virtually in most cases of CML (>95%). Chronic 
myeloid leukemia (CML) is a hematologic malignancy, 
where reciprocal translocation involving the long arms of 
chromosomes 9 and 22, resulting in the BCR/ABL fusion 
gene, plays a crucial role of its pathogenesis and a clini-
cal course. Although occurrence of fusion protein (p210) 
probably is not a sole factor responsible for pathogene-
sis of this type of leukemia and it is not present in all pa-
tients, it still represents the best target for CML therapy 
[2,4,12,41,52,64,72,91]. Earlier cytoreductive treatment 
followed by interferon alpha (IFN-a) as well as combined 
chemotherapy was used as the main treatment strategy for 
CML. Introduction of IFN-a which is nonspecific immu-
nostimulant that regulates T-cell activity improved survi-
val of CML patients but therapy was rather weakly tole-
rated. In many patients flu-like symptoms, depression and 
mood changes were observed. In addition this quite toxic 
therapy has required 3 injections per week, which was inco-
nvenient and quite expensive for many patients [19].These 
facts prompted the exploration of new drugs for the treat-
ment for CML more specific and better tolerated.
For the facts mentioned above, TKI have seemed to be in-
teresting agents, which could block proliferation of CML 
cells and lead to their apoptosis. Since TKI act directly on 
enzymes engaged in neoplastic process, they appear to be a 
good candidates used in certain types of cancer, especially, 
in disorders driven by overexpression of TK like the prote-
in product of BCR-ABL fusion gene in CML.
IMatInIb Mesylate
Imatinib mesylate, as the first TKI, has revolutionized 
the approach of CML treatment and set a new standard in 
CML patients’ therapy. A complete cytogenetic response 
was achieved in 50% to 60% of patients treated in chronic 
phase after failure with interferon therapy and in over 80% 
of newly diagnosed patients [43]. Imatinib mesylate, origi-
nally STI571 (Signal Transduction Inhibitor 571), has been 
commercially available since May 2001 and since then has 
been used as a first-line agent for newly diagnosed patients 
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– second kinase inhibitors – were approved as agents for 
first line treatment in patients with chronic phase of CML 
[87]. Imatinib, besides being better tolerated than INF-a, is 
also much more potent in prolonging progression-free su-
rvival and in reducing BCR/ABL transcript levels in CML 
[92]. Imatinib was the first agent found to be a clinically 
effective by specific inhibition of genetic aberration which 
plays a role in a malignant transformation. Its mechanism 
of action bases on blocking the ATP binding to the inacti-
ve BCR/ABL conformation, preventing thereby tyrosine 
phosphorylation on proteins responsible for intracellular si-
gnal transduction, what leads to inhibition of proliferation 
and leukemia cells apoptosis. Furthermore, recent studies 
revealed that imatinib inhibits also PDGFR (receptor for 
platelet-derived growth factor) and c-Kit (receptor for the 
cytokine stem cell factor), not solely Abl kinases [9,32,80].
Clinically CML involves three main phases: chronic, ac-
celerated and blast crisis. The latter, most advanced, is si-
milar to acute leukemia. Occasionally, also transformation 
to ALL appears [29]. Translocation (9;22) is also the most 
frequent genetic rearrangement in ALL therefore imatinib 
appeared to be a good agent for treatment of relapsed and 
refractory Ph+ ALL patients, when convectional chemo-
therapy and stem cell transplantation failed [65]. During 
progression of the ALL proliferation and accumulation of 
immature blast cells results in suppression of normal ha-
ematopoiesis [62]. Imatinib revealed to be highly effecti-
ve in patients with Ph+ ALL [86]. Unfortunately, imati-
nib used as a sole treatment in Ph+ ALL induced a short 
responses with median time to progression over 2 months 
and overall survival approximately 5 months. It promp-
ted further studies on mechanism of resistance develop-
ment to imatinib alone or in combination with other agents 
[59]. As it turned out, also in a relatively short time after 
completing clinical trials on imatinib in CML, in some 
patients, resistance and intolerance to imatinib was obse-
rved. From that time, the mechanism of resistance to ima-
tinib has been extensively studied. It was noticed that resi-
stance more common appears in accelerated phase or blast 
crisis, even after complete hematological response [74,82]. 
Underlying mechanisms of resistance have been divided 
into two main groups: BCR/ABL-dependent and -indepen-
dent. The first, ABL-kinase domain point mutation could 
change sensitivity to imatinib in BCR/ABL transformed 
cells. Presence of such mutation leads to lower sensitivity 
to TKI via alteration of amino acids residues in inhibitor 
binding site or preventing enzyme from achieving inactive 
conformation required for imatinib binding [35,76]. Up till 
now more than 50 different mutants have been described, 
some of them are characteristic for chronic phase, accele-
rated or blast crisis. The scientists observed, that most of 
these mutations are intimately concerned with amino acids 
substitution at seven residues (M244V, G250E, Y253F/H, 
E255K/V, T315I, M351T and F359V). It was also demon-
strated, that severity of disease has an impact on occurren-
ce of resistance-associated mutations. CML patients in ad-
vanced phases and Ph+ ALL patients more often develop 
mutation. Especially presence of mutation at P-loop (gly-
cine-rich sequence spanning amino-acids from 248 to 256, 
which binds with imatinib through hydrogen and van der 
Waals bonds) is related to decreased sensitivity to imati-
nib via destabilization of conformation required for ima-
tinib biding. In particular, complete resistance to imatinib 
was noticed in patients with T315I mutation described by 
Gorre et al. in 2001 [27], and was also considered as a bad 
prognostic factor. Thereby presence of mentioned muta-
tion possesses the major warning that therapeutic strategy 
should be reconsidered [7,79]. The second usually reported 
Fig. 1.   Mechanism of action of tyrosine kinase. 
Tyrosine kinase catalyzes the transfer of a 
phosphate group from ATP to the side chains 
of tyrosine residues, altering inactive into active 
phosphorylated conformation of protein
Fig. 2.   Fusion of chromosomes 9 and 22 results in 
generation of the Philadelphia chromosome. 
Philadelphia chromosome is generated by 
translocation t(9,22)(q34: q11) which produces 
aberrant tyrosine kinase BCR/ABL. This mutation 
is present virtually in most cases of CML (>95%)
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its uncontrolled amplification, however its more pronoun-
ced in in vitro studies than in clinic [27,34,73].
Other TK are also essential for signal transduction required 
to control proliferation and apoptosis. Overexpression of 
Lyn kinase (member of the Src family of protein tyrosine 
kinases, which is mainly expressed in hematopoetic cells) 
appears to play an important role in the survival of CML 
cells that are resistant to imatinib. Studies of Donato et al. 
[15] on CML cell line K562R have shown that Lyn kina-
se is responsible for sensitivity of CML cells to the inhi-
bition of BCR/ABL kinase, and that there are differences 
in Lyn regulation between imatinib-sensitive and imati-
nib-resistant CML cell lines. Further studies also confirm 
this finding [61,93].
Other factors associated with enhanced proliferation repre-
sents BCR/ABL independent cytogenetic aberrations. The 
main cause for imatinib resistance in this group of patients 
is a clonal evolution with presence of additional cytoge-
netic aberration. Hochhaus et al. [34] studies revealed that 
novel cytogenetic aberrations could be detected in 19 of 
36 with refractory CML patients. In 13 aneuploidy asso-
ciation with chromosomal instability was found. Also the 
loss of one p53 allele, caused by changes in the short arm 
of chromosome 17 occurred in seven patients [17].
Other groups also studied an impact of P-glycoprotein (P-
gp ABCB-1) overexpression on imatinib resistance, since 
imatinib is effectively effluxed by P-gp. This integral mem-
brane protein is one of members of ATP-binding cassette 
(ABC) transporters, which is composed of two homolo-
gous parts, each containing the site for binding cytosolic 
ATP. The energy obtained from ATP-hydrolysis is used to 
transport P-gp substrates and keep them out of cells dimi-
nishing their intracellular concentration [37,38]. The stu-
dies showed the correlation between accumulation of P-gp 
protein and worse response to imatinib also the severity 
of the disease was dependent on P-gp expression. Since 
P-gp is a product of multi-drug resistance gene – MDR1, 
some investigations found polymorphism of MDR1 reve-
aled molecular resistance to imatinib [13,40].
Other important factor involved in imatinib cellular distri-
bution is h-OTC-1 protein (human organic cation transpor-
ter-1). Since imatinib is moved into cell via mechanism 
of active transport by h-OTC-1, impaired function could 
also lead to imatinib resistance. This hypothesis faced by 
White et al. [89], where authors proved that patients with 
low expression of this protein exhibit suboptimal response 
to imatinib. In addition, they used various doses of imati-
nib and observed that patients who express low levels of 
h-OTC-1 and receive higher doses (more than 600 mg) of 
imatinib responded better to therapy. Moreover, imatinib 
plasma concentration was assayed in patients with good re-
sponses and compared with those with imatinib resistance. 
The obtained results suggest relation between response to 
imatinib and its plasma concentration. This fact is proba-
bly associated with strong binding of imatinib to alpha1-
-acid glycoprotein [48].
Specific inhibition of TK was also found as a therapeutic 
strategy in gastrointestinal stromal tumors (GISTs) [47].
second generatIon tyrosIne kInase InhIbItors
Although imatinib has proved efficacy in a first-line the-
rapy for CML and Ph+ ALL patients, above mentioned 
observations on resistance prompted further studies in 
the quest for new agents among TKI which could produ-
ce a response in patients with imatinib-resistant or refrac-
tory CML or Ph+ALL. Novel compounds of this group of 
drugs, represent second generation TKI, which turned out 
to be a good option for CML patients who do not tolerate 
imatinib, harbor the mutation or exhibit imatinib resistan-
ce from another reasons.
dasatInIb
Dasatinib (formerly BMS354825) is a multitarget TKI ef-
fective in the majority of imatinib resistance leukemias. 
It blocks activity of BCR/ABL and all members of Src-
family kinases. Like imatinib, it has also a capability to 
block other kinases such as c-KIT, PDGFR and ephrin re-
ceptor kinase [58]. Initially, since June 2006 dasatinib has 
been used for imatinib-resistant or intolerant CML and Ph+ 
ALL and since October 2010 it has been approved in 100 
mg once a day as a first-line treatment of chronic phase for 
newly diagnosed CML.
Like imatinib, it is an ATP-competitive kinase inhibitor but 
it has a different chemical structure [50]. As it was mentio-
ned, some of mutations causing resistance to imatinib were 
involved in changing kinase conformation, making it una-
vailable to this compound. Dasatinib seems to be more ef-
fective than imatinib because of its mechanism of binding 
to the ABL kinase domain, which doesn’t require an inac-
tive conformation. It can bind to both the inactive and ac-
tive forms of BCR/ABL. Thanks that dasatinib can over-
come almost all imatinib-resistant forms of Bcr-Abl. Only 
the T315I mutant remains resistant also to this second ge-
neration TKI. Moreover, the in vitro studies proved that 
dasatinib is over 300-fold more potent against wild-type 
BCR/ABL than imatinib [56,58,77,83]. As mentioned abo-
ve, clinical trials revealed that unsatisfactory results after 
treatment with imatinib in some patients with CML may 
be also related to overexpression of Src kinases, especial-
ly Hck and Lyn [90]. Taking under consideration that da-
satinib is also active against this family of kinases, it ap-
pears to be a perfect compound to overcome this source of 
imatinib resistance [15,61]. Konig at al. [45] revealed that 
Src phosphorylation is also enhanced in progenitor cells 
and it is involved in leukemogenesis in CML. This is ano-
ther resistance to imatinib mechanism thereby dasatinib in 
regard of targeting on Src signaling pathway could addi-
tionally target on progenitors cells in CML. It was proved 
that dasatinib reduced Src level in CD34+ and in more pri-
mitive CD34+CD38– cells in all phases of CML. Studies 
also showed that dasatinib inhibits both BCR/ABL kina-
se-dependent and kinase-independent Src activation, whi-
le imatinib acts solely on BCR/ABL kinase mediated Src 
activation. In experiment on CML CD34+ cells exposed to 
imatinib (5 Amol/L) or dasatinib (0.01–0.15 Amol/L) with 
or without exogenous growth factor (GF) authors found that 
dasatinib in the absence of GF was able to reduce MAPK, 
Akt, and Stat5 (signal transducer and activator of transcrip-
tion 5) expression [15,93]. Stat proteins and its downstream 
transducers play a crucial role in many physiopathological 
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cell cycle. Stat5 is the most important protein of Stat fami-
ly. Deregulation of Stat5 signaling pathways is related to 
immunosuppression, enhanced proliferation and survival 
of pathological cells. Hoelbl et al. [36] has observed that 
Stat5 is crucial for viability and proliferation of leukaemic 
cells in Ph-positive CML and ALL. They proved that inhi-
bition of Stat5 led to G0/G1 cell cycle arrest and apoptosis 
of leukemic cells in vitro and elimination of myeloid and 
lymphoid leukemia cells in vivo. Nam et al. [55] observed 
that dasatinib has an ability to decrease levels of phospho-
rylated Stat5 and Stat5-DNA binding activity. Authors fur-
ther observed reduced expression of some Stat5 targets such 
as Bcl-x, Mcl-1 and cyclin D1 which are related to cancer 
progression. Hence, inhibition of Stat5 – as well as alone 
or in combination with BCR/ABL – may pose a new ef-
fective strategy toward treatment of CML.
As has been observed in many studies that Src kinases, 
especially Lyn, which has the greatest expression in my-
eloid cells, play an important role in myelopoiesis. Hence, 
inhibition of its activity appears to be a good therapy of 
acute myeloid leukemia (AML). Interestingly, to prove that 
silencing of Lyn gives good result in arrestment of myeloid 
cell growth, the scientists used interference with siRNA to 
decrease level of Lyn kinases. Nonetheless, RNA interfe-
rence has not been used yet in therapeutic regimens, thus 
they have continued this study with dasatinib as the Src ki-
nase inhibitor. After 60-minute incubation with dasatinib 
at nanomolar concentrations, the inhibition was observed 
in all of studied cell lines. The scientists used in this study 
most characteristic cell lines for AML. The result of some 
other experiments have revealed that dasatinib potently in-
hibited the growth of primary AML blasts.
Dasatinib efficacy against c-Kit augments its further uti-
lization in AML. Guerrouahen et al. [30] used Mo7e cells 
line, which harbor an activating mutation of Kit and treated 
with dasatinib. They observed direct inhibition of c-Kit and 
effective inhibition of the growth of Mo7e cells [36,53,94].
Another important factor affecting effectiveness of the-
rapy is mechanism of drug cellular transport. It has been 
also mentioned that expression of ATP binding-cassette 
member – ABCB-1 – can influence on imatinib intracellu-
lar concentration and thereby limiting its efficacy in CML 
patients. In contrast to imatinib, dasatinib has not been a 
substrate of P-gp, therefore it appeared to be more effecti-
ve than imatinib due to higher intracellular concentration 
in hematopoietic progenitor cells [81]. Surprisingly, the re-
cent results revealed that dasatinib has also an affinity for 
dissolving in lipids and could also be a substrate of ABCB-
1. Hiwase et al. [33] also confirmed that dasatinib is also a 
substrate of ABCB-2 efflux transporter. Other protein in-
volved in cellular drug transport is h-OTC-1. As has been 
shown imatinib uptake is dependent on this active protein, 
which function depends on temperature. Studies on dasa-
tinib indicated no difference between dasatinib concentra-
tions in 4°C and 37°C, what suggests that dasatinib upta-
ke is a more passive process. Also inhibition of h-OCT-1 
did not change dasatinib concentration, in contrast to ima-
tinib. These data proved that dasatinib uptake does not de-
pend on h-OCT-1 level. Therefore treatment with dasati-
nib may be a good strategy for patients with low h-OCT-1 
expression [24,42]. Above findings suggest that characte-
rization of the cellular uptake and efflux pathways of the 
TKI may help to define appropriate and effective therapy 
for individual CML patients.
Studies on dasatinib therapy for newly diagnosed CML pa-
tients in comparison with the treatment with standard dose 
of imatinib has shown, that patients with chronic-phase tre-
ated with dasatinib, in 100 mg/day, achieved a complete 
cytogenetic response and a major molecular response to a 
greater extent than those treated with imatinib 400 mg/day. 
Additionally, dasatinib induced responses faster and more 
potently than imatinib, therefore on October 28, 2010, it 
was approved by the US Food and Drug Administration 
at 100 mg once daily as an agent used in the treatment for 
patients with a newly diagnosed chronic phase and at 70 
mg twice daily in patients with more advanced phases of 
CML [44].
It has also been proved that dasatinib is effective in patient 
with Ph-positive ALL. Recent studies have shown a big 
efficacy of dasatinib in untreated patient with Ph-positive 
ALL. Foa et al. [22] have revealed that all of patients with 
newly diagnosed Ph-positive ALL who were treated with 
dasatinib, combined with steroids, achieved complete re-
sponse within one month on treatment. Also in Ravandi’s 
study [68] has shown that dasatinib in combination with 
hyperCVAD caused complete response in 33 (94%) pa-
tients. These findings indicate that dasatinib as a first-li-
ne treatment in Ph-positive ALL, combined with stero-
ids and chemotherapy, appears to be a good therapeutic 
option [68]. Immunomodulatory character of dasatinib ap-
pears to be very controversial. Some studies have sugge-
sted that dasatinib, in regard of targeting Src kinases, may 
have an suppressive character. In 2007 Schade et al. [75] 
have shown, that dasatinib can inhibit T-cell activation 
and proliferation via inhibition of LCK, which is crucial 
for T-cell receptor (TCR) signaling pathway. They obse-
rved inhibition of TCR-mediated signal transduction, cel-
lular proliferation, cytokine production, and in vivo T-cell 
responses. This finding encouraged further studies on im-
munomodulatory proprieties of dasatinib. Another aspect 
of immunosuppression is inhibition of NK cells cytotoxi-
city as some Src kinases are essential for maintenance of 
this NK function. The results of the study [6] revealed that 
dasatinib reduced NK cell cytotoxicity with maximal ef-
fect achieved at about 25 nM. But there has not been pro-
ved in in vivo studies yet. Perhaps in the case of T-cells 
only high doses of dasatinib have a suppressive properties. 
This findings, especially associated with suppression of 
T-cell activity appears to be helpful in therapy for patients 
with molecular relapse in CML after haploidentical BMT 
with chronic GVHD (graft-versus-host disease). Breccia 
et al. [8] carried the investigation on patients, who relap-
sed and had chronic liver GVHD after BMT. They have 
shown that dasatinib at low doses was well-tolerated and 
restored the molecular response and improved the hepa-
tic dysfunction caused by GVHD. Interestingly, the recent 
publications have shown, that dasatinib influences on in-
crease of lymphocytosis in patient with Ph positive leuke-
mia. In 2010, Kreutzman and colleagues [46] observed the 
presence of clonal cytotoxic T and NK cells in over 80% 
(15 of 18) of patients with CML during imatinib therapy. 
What is more interesting, they described increase of the 
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Mustjoki et al. [54] have shown increase of NK/T cells in 
22 patients with CML and Ph+ ALL treated with dasatinib. 
He also demonstrated correlation between the development 
of lyphocytosis and better effects of therapy. Mechanism 
of this expansion has not been explained yet, but compa-
rable results have been observed by others. Interestingly, 
only patients who developed lymphocytosis demonstrated 
higher rates of cumulative complete cytogenetic response 
and major cytogenetic response at one year [8,10,67,75].
nIlotInIb
Other second-generation TKI – nilotinib – originally ter-
med AMNI07, like dasatinib, has been initially used in 
the treatment for adults in chronic and accelerated phase 
of Ph-positive CML resistant or intolerant to imatinib. In 
June 2010 nilotinib received FDA approval as a first-line 
therapy in patients with chronic phase of CML. Nilotinib 
was designed based on detailed molecular studies on ima-
tinib’s structure. It is improved derivative of imatinib and, 
like imatinib, also bind to the inactive conformation of Abl. 
It has a similar chemical structure, but demonstrates bet-
ter topographical fit for the ABL protein thanks to modi-
fication of the methylpiperazinyl group of imatinib, and it 
is approximately 30-fold more effective than imatinib as 
it was shown in cell lines expressing BCR/ABL (fig. 3) 
[70,88]. Data from Weisberg et al. [88] suggest that nilo-
tinib selectively inhibits BCR/ABL, Kit, and PDGFR ty-
rosine kinases, but does not influences any of the kinases 
required for IL-3 signaling, including JAK2. Nilotinib, in 
contrast to dasatinib, has minimal effect on Src family ki-
nases, what has been associated with nilotinib resistance 
in vitro in samples with increased expression of Lyn ki-
nase. Since Lyn is involved in erythropoiesis and Hck is 
essential for the survival of myeloid cells and B lympho-
cytes, it has been proposed that nilotinib may have a more 
safe side effect profile especially with regard to myelosup-
pression than dasatinib [14,49,51]. From October 29, 2007 
nilotinib 400 mg twice daily has been approved in the US 
and Europe for patients in chronic and accelerated phases 
of CML who are resistant or intolerant to imatinib. After 
further trials, imatinib and nilotinib in newly diagnosed 
CML patients, nilotinib 300 mg twice a day was approved 
in the US for previously untreated patients with chronic 
phase of CML [88].
Laboratory data on nilotinib have revealed that inhibi-
tion of cell growth by nilotinib was associated with induc-
tion of apoptosis [88]. Similarly to dasatinib, has activity 
against most of the mutated forms of BCR/ABL kinase. 
However, despite grater efficacy, resistance still occurs in-
cluding Y253H, E255K/V, F359C/V and T315I mutants. 
This patients, treated with nilotinib after imatinib failure, 
had significantly shorter progression-free survival. Also in 
vitro studies have revealed lower sensitivity of these muta-
ted clones to nilotinib [69,88]. Since several studies under-
lined the probable role of Bim expression during imatinib-
-induced apoptosis, nilotinib also could act via regulation 
of Bim levels, that results in CML cell death [1,18]. Belloc 
and colleagues [5] experimentally verified whether Bim ac-
cumulation was linked to BCR/ABL tyrosine kinase activi-
ty. They inhibit BCR/ABL autophosphorylation using ima-
tinib and nilotinib. Both agents inhibited 80% of ABL and 
BCR/ABL autophosphorylation. This inhibition was accom-
panied by a two fold increase in relative BimEL expres-
sion. Accumulation of Bim was followed by mitochondrial 
apoptosis. As far as impact on T regulatory cells is con-
cerned, comparing results of studies on these three kinase 
inhibitors used in front-line CML therapy, we can observe 
that imatinib inhibits the proliferation and function of Tregs 
and CD8+ T cells in concentrations in a range 1–5 µM. [11] 
while for dasatinib is 5–10 nM [21]. Results of Fei et al. 
[20] studies on nilotinib impact on Tregs revealed that ni-
lotinib inhibited the proliferation and suppressive capacity 
of Tregs but in a dose-dependent manner. The production 
of cytokines secreted by Tregs and CD4+CD25– effector 
T cells was only inhibited at high concentrations of niloti-
nib exceeding the mean therapeutic serum concentrations 
of the drug in patients. Although, these results showed that 
nilotinib did not attenuate the function of Tregs at clinical 
relevant doses, this finding might be utilized after alloge-
neic stem cell transplantation.
Introduction of second generation kinase inhibitors to Ph+ 
hematological diseases has revolutionized therapy of CML 
and ALL. Although responses can be achieved in many pa-
tients using a second-generation TKI after the failure of 
imatinib or other therapy, the responses have still tended to 
Fig. 3.   Chemical structures of imatinib, dasatinib 
and nilotinib and their localization in tyrosine 
kinase BCR/ABL; A – Chemical structure of 
the first generation tyrosine kinase inhibitor 
– imatinib and its localization in tyrosine 
kinase BCR/ABL, B – Chemical structures of 
the second generation tyrosine kinase inhibitors 
– dasatinib and nilotinib and their localization 
in tyrosine kinase BCR/ABL
A
B
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tients, such as those harboring T315I mutation, have ne-
eded new agents for their therapy. Therefore there is fe-
rvent need for further development of new generation TKI.
bosutInIb
Bosutinib originally termed SKI-606, similarly to dasati-
nib is a dual Abl-Src kinase inhibitor. This Src kinase in-
hibitor was able to inhibit Fgr and Lyn TK even at pico-
molar concentrations. Further studies have revealed that 
it also targets Abl tyrosine kinase activity in low concen-
trations and could be more effective than imatinib but sli-
ghtly weaker than dasatinib [63]. Bosutinib, in compari-
son to imatinib, could bind intermediate conformation of 
Abl [70] (tab. 1).
Bosutinib was proved to be effective in several imatinib-
-resistant cell lines harboring different point mutants, the 
T315I mutation still remained undefeated. Bosutinib was 
effective as a second- and third-line treatment in patients 
who failed imatinib or dasatinib therapy.
Bosutinib is not yet approved by FDA for first-line thera-
py in chronic phase of CML. In phase I/II clinical trials, 
this compound yielded promising response rates, redu-
ced toxicity and good tolerability in imatinib-resistant 
or -intolerant CML patients. 18-month evaluation of the 
BELA trial comparing bosutinib 500 mg/day with imati-
nib 400 mg/day in newly diagnosed patients presented at 
the European Hematology Association’s Annual Congress 
2011 in London has been very promising. Faster and de-
epen responses were observed in patient treated with bo-
sutinib than imatinib with fewer events of progression. The 
drug was well tolerated as long as initial gastrointestinal 
and liver side effects were managed well – with dose mo-
difications or temporary interruptions [23]. In comparison 
to imatinib and dasatinib, bosutinib has only weak activi-
ty against PDGFR and KIT. This fact could explain safe-
ty since many side effects associated with imatinib such 
as edema, skin rash or inhibition of normal hemopoiesis 
have been related to the inhibition of PDGFR and/or KIT. 
Interestingly, bosutinib is active against a broader spec-
trum of kinases than originally was thought. Beside abo-
ve mentioned ABL and SRC kinases this TKI targets TEC 
family kinases, which play a pivotal role in the regulation 
of the immune functions, especially BTK. Many of them, 
for example EPHB4, FER, PTK2 (FAK), PYK2, SYK and 
TNK2 are also often overexpressed in human cancers and 
are associated with poor prognosis. Also some kinases im-
portant for signal transduction, including MAPK signaling 
pathway are sensitive to bosutinib inhibition. Importantly, 
this compound is the first kinase inhibitor shown to target 
Ca2t/calmodulin-dependent protein (CAMK2G), which 
has been recently linked to myeloid leukemia cell prolife-
ration. CAMK2G is involved in regulating signaling pa-
thways controlling the proliferation of myeloid leukemia 
cells. Moreover, bosutinib is probably the first compound, 
among CAMK2G inhibitors, directly binding the adenosi-
ne triphosphate binding site of CAMK2G [71,78].
Since interactions between ABC multidrug transporters 
and several first-generation, small-molecule TKI are im-
portant in pharmacokinetics scientists have studied influen-
ce of MDR-ABC transporters on bosutinib. Hegedűs et al. 
[31] have found that neither ABCB1 nor ABCG2 interact 
with bosutinib at therapeutical concentration. These data 
have shown that multidrug resistance ATP-binding casset-
te (MDR-ABC) transporters cannot be responsible for bo-
sutinib resistance and ABCB1 and ABCG2 could only sli-
ghtly modify the cytotoxic effect of bosutinib.
next generatIons of tyrosIne kInase InhIbItIors
Despite the great progress in the treatment of CML thanks 
to above described TKIs, scientists still have been searching 
for new, more effective and more potent agents, especial-
ly toward resistant mutants, such as T315I. The first novel 
potent inhibitor of BCR/ABL and aurora kinases (Aks) 
that shows clinical activity against T315I mutated form of 
BCR/ABL was MK-0457 [25]. Unfortunately this compo-
und exerted serious cardiac toxicity [87]. Next novel TKI 
could be ponatinib (AP24534) and danusertib (formerly 
PHA-739358) [57]. Danusertib is a small molecule 3-ami-
nopyrazole derivative that additionally inhibits some other 
cancer relevant TK such as wild type and mutated ABL, 
RET, TRK-A and FGFRs. Gontarewicz et al. [26] in their 
publication revealed potent antiproliferative effects of PHA-
739358 in CD34+ cells derived from untreated and imati-
nib-resistant CML patients in chronic phase or blast crisis, 
including those harboring the T315I mutation. Recently, in 
phase I clinical trials danusertib has been tested in patient 
with solid tumors. The multicenter phase II study has recru-
ited 12 relapsing CML patients. Objective clinical respon-
ses to danusertib have been observed in two CML patients 
with T315I mutations of BCR/ABL, with an acceptable to-
lerability and safety profile [60]. The aurora kinases family 
inhibitor ponatinib has demonstrated a potent activity aga-
inst an wide array of BCR/ABL variants including T315I 
mutants and could also target other therapeutically relevant 
kinases such as FLT3, FGF, VEGF and PDGF, and c-KIT 
[28]. This agent is currently in a pivotal Phase II clinical 
trial as a treatment for CML patients or Ph+ ALL resistant 
to second generation TKIs. Ponatinib was very well tole-
rated until the determined maximum tolerated dose of 45 
mg daily is not exceeded. This compound seems to be very 
promising as a second- or third-line treatment for patients 
with refractory CML and ALL, especially those harboring 
multidrug-resistant mutations of BCR/ABL.
Summarizing, as we have shown in this review, TKI have 
revolutionized CML therapies in a very short period of time. 
They have also a broader therapeutic array and could be 
TKI  Target Required BCR-ABL 
conformation
Imatinib BCR/ABL, PDGFR, C-KIT, EPH inactive 
Dasatinib BCR/ABL, PDGFR, C-KIT, EPH, 
SRC
both active and 
inactive
Nilotinib BCR/ABL, PDGFR, C-KIT, EPH, 
SRC inactive
Bosutinib BCR/ABL, SRC, TEC, CAMK2G, 
PDGFR and C-KIT intermediate
Table 1. Summarized features of tyrosine kinase inhibitors (TKI) [66,84]
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       -               -               -               -               -       used in PH+ ALL and GIST patients. TKI still represent 
one of the most interesting anticancer compounds giving a 
hope for a cure of patient. Better understanding of genetic 
alterations and oncogenic pathways in combination with 
knowledge about proprieties of TKI could lead to modifi-
cations of the structure of these compounds that could al-
ter the mechanism of action improving the effectiveness 
of these agents.
references
  [1] Aichberger K.J., Mayerhofer M., Krauth M.T., Vales A., Kondo R., 
Derdak S., Pickl W.F., Selzer E., Deininger M., Druker B.J., Sillaber 
C., Esterbauer H., Valent P.: Low-level expression of proapoptotic 
Bcl-2-interacting mediator in leukemic cells in patients with chronic 
myeloid leukemia: role of BCR/ABL, characterization of underlying 
signaling pathways, and reexpression by novel pharmacologic com-
pounds. Cancer Res., 2005; 65: 9436–9444
  [2] Al Achkar W., Wafa A., Mkrtchyan H., Moassass F., Liehr T.: A rare 
case of chronic myeloid leukemia with secondary chromosomal chan-
ges including partial trisomy 17q21 to 17qter and partial monosomy 
of 16p13.3. Mol. Cytogenet., 2010; 3: 6
  [3] Arora A., Scholar E.M.: Role of tyrosine kinase inhibitors in cancer 
therapy. J. Pharmacol. Exp. Ther., 2005; 315: 971–979
  [4] Belli C., Alú M.F., Alfonso G., Bianchini M., Larripa I.: Novel variant 
Ph translocation t(9;22;11)(q34;q11.2;p15)inv(9)(p13q34) in chronic 
myeloid leukemia involving a one-step mechanism. Cytogenet. Genome 
Res., 2011; 132: 304–308
  [5] Belloc F., Moreau-Gaudry F., Uhalde M., Cazalis L., Jeanneteau M., 
Lacombe F., Praloran V., Mahon F.X.: Imatinib and nilotinib induce 
apoptosis of chronic myeloid leukemia cells through a Bim-dependant 
pathway modulated by cytokines. Cancer Biol. Ther., 2007; 6: 912–919
  [6] Blake S.J., Bruce Lyons A., Fraser C.K., Hayball J.D., Hughes T.P.: 
Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood, 
2008; 111: 4415–4416
 [7] Breccia M., Alimena G.: Resistance to imatinib in chronic myelo-
id leukemia and therapeutic approaches to circumvent the problem. 
Cardiovasc. Hematol. Disord. Drug Targets, 2009; 9: 21–28
 [8] Breccia M., Cannella L., Stefanizzi C., Carotti A., Santopietro M., 
Alimena G.: Efficacy of dasatinib in a chronic myeloid leukemia patient 
with disease molecular relapse and chronic GVHD after haploidenti-
cal BMT: an immunomodulatory effect? Bone Marrow Transplant., 
2009; 44: 331–332
  [9] Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker 
B.J., Lydon N.B.: Abl protein-tyrosine kinase inhibitor STI571 inhi-
bits in vitro signal transduction mediated by c-kit and platelet-derived 
growth factor receptors. J. Pharmacol. Exp. Ther., 2000; 295: 139–145
 [10] Carlson R.H.: CML: Dasatinib-related lymphocytosis associated with 
improved response in DASISION subanalysis. Oncology Times UK, 
2011; 33: 31[abstract number 358]
 [11] Chen J., Schmitt A., Giannopoulos K., Chen B., Rojewski M., Döhner 
H., Bunjes D., Schmitt M.: Imatinib impairs the proliferation and func-
tion of CD4+CD25+ regulatory T cells in a dose-dependent manner. 
Int. J. Oncol., 2007; 31: 1133–1139
 [12] Chen Y., Peng C., Li D., Li S.: Molecular and cellular bases of chro-
nic myeloid leukemia. Protein Cell, 2010; 1: 124–132
  [13] Deenik W., van der Holt B., Janssen J.J., Chu I.W., Valk P.J., 
Ossenkoppele G.J., van der Heiden I.P., Sonneveld P., van Schaik 
R.H., Cornelissen J.J.: Polymorphisms in the multidrug resistance 
gene MDR1 (ABCB1) predict for molecular resistance in patients 
with newly diagnosed chronic myeloid leukemia receiving high-dose 
imatinib. Blood, 2010; 116: 6144–6145
 [14] Deremer D.L., Katsanevas K., Ustun C.: Critical appraisal of nilotinib 
in frontline treatment of chronic myeloid leukemia. Cancer Manag. 
Res., 2011; 3: 65–78
  [15] Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., 
Talpaz M.: BCR-ABL independence and LYN kinase overexpression in 
chronic myelogenous leukemia cells selected for resistance to STI571. 
Blood, 2003; 101: 690–698
  [16] Druker B.J., Lydon N.B.: Lessons learned from the development of 
an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. 
Clin. Invest., 2000; 105: 3–7
  [17] Duesberg P., Stindl R., Hehlmann R.: Origin of multidrug resistan-
ce in cells with and without multidrug resistance genes: chromosome 
reassortments catalyzed by aneuploidy. Proc. Natl. Acad. Sci. USA, 
2001; 98: 11283–11288
 [18] Essafi A., Fernández de Mattos S., Hassen Y.A., Soeiro I., Mufti G.J., 
Thomas N.S., Medema R.H., Lam E.W.: Direct transcriptional regu-
lation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-
Abl-expressing cells. Oncogene, 2005; 24: 2317–2329
 [19] Fausel C.: Targeted chronic myeloid leukemia therapy: seeking a cure. 
J. Manag. Care Pharm., 2007; 13(Suppl.A): 8–12
  [20] Fei F., Yu Y., Schmitt A., Rojewski M.T., Chen B., Greiner J., Götz 
M., Bunjes D., Schmitt M.: Effects of nilotinib on regulatory T cells: 
the dose matters. Mol. Cancer, 2010; 9: 22
  [21] Fei F., Yu Y., Schmitt A., Rojewski M.T., Chen B., Greiner J., Götz 
M., Guillaume P., Döhner H., Bunjes D., Schmitt M.: Dasatinib exerts 
an immunosuppressive effect on CD8+ T cells specific for viral and 
leukemia antigens. Exp. Hematol., 2008; 36: 1297–1308
  [22] Foa R., Vitale A., Guarini A., De Propris A.S., Elia R., Cimino G., 
Luppi M., Castagnola C., Sica S., Nieddu R., Piersantelli M., Ferrara 
F., Nobile F., Fanin R., Fabbiano F., Vignetti M., Fazi P., Soverini 
S., Mandelli F., Martinelli G., Meloni G., Baccarani M.: Dasatinib 
monotherapy effective and feasible as first-line treatment of adult 
Philadelphia-chromosome positive acute lymphoblastic leukemia: 
Final results of the GIMEMA LAL1205 study. Blood, 2008; 112: 119 
[abstract number 305]
  [23] Gambacorti-Passerini C., Cortes J.E., Kim D., Kantarjian H., Khattry 
N., Lipton J.H., Powell C., Harris P., Countouriotis A.M., Brummendorf 
T.H.: Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chro-
nic phase chronic myeloid leukemia (CP CML) in the BELA trial: 
18-month follow-up. J. Clin. Oncol., 2011; 29 [abstract number 6509]
  [24] Giannoudis A., Davies A., Lucas C.M., Harris R.J., Pirmohamed M., 
Clark R.E.: Effective dasatinib uptake may occur without human or-
ganic cation transporter 1 (hOCT1): implications for the treatment 
of imatinib-resistant chronic myeloid leukemia. Blood, 2008; 112: 
3348–3354
  [25] Giles F.J., Cortes J., Jones D., Bergstrom D., Kantarjian H., Freedman 
S.J.: MK-0457, a novel kinase inhibitor, is active in patients with chro-
nic myeloid leukemia or acute lymphocytic leukemia with the T315I 
BCR-ABL mutation. Blood, 2007; 109: 500–502
  [26] Gontarewicz A., Balabanov S., Keller G., Colombo R., Graziano A., 
Pesenti E., Benten D., Bokemeyer C., Fiedler W., Moll J., Brümmendorf 
T.H.: Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by 
the small molecule inhibitor PHA-739358 is effective against imati-
nib-resistant BCR-ABL mutations including T315I. Blood, 2008; 111: 
4355–4364
  [27] Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao 
P.N., Sawyers C.L.: Clinical resistance to STI-571 cancer therapy cau-
sed by BCR-ABL gene mutation or amplification. Science, 2001; 293: 
876–880
  [28] Gozgit J.M., Wong M.J., Wardwell S., Tyner J.W., Loriaux M.M., 
Mohemmad Q.K., Narasimhan N.I., Shakespeare W.C., Wang F., Druker 
B.J., Clackson T., Rivera V.M.: Potent activity of ponatinib (AP24534) 
in models of FLT3-driven acute myeloid leukemia and other hemato-
logic malignancies. Mol. Cancer Ther., 2011; 10: 1028–1035
  [29] Griffin J.D., Todd R.F. 3rd, Ritz J., Nadler L.M., Canellos G.P., 
Rosenthal D., Gallivan M., Beveridge R.P., Weinstein H., Karp D., 
Schlossman S.F.: Differentiation patterns in the blastic phase of chro-
nic myeloid leukemia. Blood, 1983; 61: 85–91
  [30] Guerrouahen B.S., Futami M., Vaklavas C., Kanerva J., Whichard 
Z.L., Nwawka K., Blanchard E.G., Lee F.Y., Robinson L.J., Arceci 
R., Kornblau S.M., Wieder E., Cayre Y.E., Corey S.J.: Dasatinib in-
hibits the growth of molecularly heterogeneous myeloid leukemias. 
Clin. Cancer Res., 2010; 16: 1149–1158
  [31] Hegedus C., Ozvegy-Laczka C., Apáti A., Magócsi M., Német K., 
Orfi L., Kéri G., Katona M., Takáts Z., Váradi A., Szakács G., Sarkadi 
B.: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and 
ABCG2: implications for altered anti-cancer effects and pharmaco-
logical properties. Br. J. Pharmacol., 2009; 158: 1153–1164
  [32] Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., Zigler 
A.J.: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, 
a selective tyrosine kinase inhibitor. Blood, 2000; 96: 925–932
Postepy Hig Med Dosw (online), 2011; tom 65: 819-828
826 
       -               -               -               -               -        [33] Hiwase D.K., Saunders V., Hewett D., Frede A., Zrim S., Dang P., Eadie 
L., To L.B., Melo J., Kumar S., Hughes T.P., White D.L.: Dasatinib 
cellular uptake and efflux in chronic myeloid leukemia cells: thera-
peutic implications. Clin. Cancer Res., 2008; 14: 3881–3888
 [34] Hochhaus A., Kreil S., Corbin A.S., La Rosée P., Müller M.C., Lahaye 
T., Hanfstein B., Schoch C., Cross N.C., Berger U., Gschaidmeier H., 
Druker B.J., Hehlmann R.: Molecular and chromosomal mechani-
sms of resistance to imatinib (STI571) therapy. Leukemia, 2002; 16: 
2190–2196
  [35] Hochhaus A., La Rosée P.: Imatinib therapy in chronic myelogeno-
us leukemia: strategies to avoid and overcome resistance. Leukemia, 
2004; 18: 1321–1331
  [36] Hoelbl A., Schuster C., Kovacic B., Zhu B., Wickre M., Hoelzl M.A., 
Fajmann S., Grebien F., Warsch W., Stengl G., Hennighausen L., Poli 
V., Beug H., Moriggl R., Sexl V.: Stat5 is indispensable for the ma-
intenance of bcr/abl-positive leukaemia. EMBO Mol. Med., 2010; 2: 
98–110
 [37] Hrycyna C.A.: Molecular genetic analysis and biochemical characteri-
zation of mammalian P-glycoproteins involved in multidrug resistan-
ce. Semin. Cell Dev. Biol., 2001; 12: 247–256
  [38] Hrycyna C.A., Ramachandra M., Germann U.A., Cheng P.W., Pastan 
I., Gottesman M.M.: Both ATP sites of human P-glycoprotein are es-
sential but not symmetric. Biochemistry, 1999; 38: 13887–13899
  [39] Hunter T.: The role of tyrosine phosphorylation in cell growth and di-
sease. Harvey Lect., 1998–1999; 94: 81–119
  [40] Illmer T., Schaich M., Platzbecker U., Freiberg-Richter J., Oelschlägel 
U., von Bonin M., Pursche S., Bergemann T., Ehninger G., Schleyer 
E.: P-glycoprotein-mediated drug efflux is a resistance mechanism of 
chronic myelogenous leukemia cells to treatment with imatinib me-
sylate. Leukemia, 2004; 18: 401–408
 [41] Johansson B., Fioretos T., Mitelman F.: Cytogenetic and molecular ge-
netic evolution of chronic myeloid leukemia. Acta Haematol., 2002; 
107: 76–94
  [42] Kamath A.V., Wang J., Lee F.Y., Marathe P.H.: Preclinical pharma-
cokinetics and in vitro metabolism of dasatinib (BMS-354825): a po-
tent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. 
Cancer Chemother. Pharmacol., 2008; 61: 365–376
  [43] Kantarjian H., Shah N.P., Hochhaus A., Cortes J., Shah S., Ayala M., 
Moiraghi B., Shen Z., Mayer J., Pasquini R., Nakamae H., Huguet F., 
Boqué C., Chuah C., Bleickardt E., Bradley-Garelik M.B., Zhu C., 
Szatrowski T., Shapiro D., Baccarani M.: Dasatinib versus imatinib 
in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. 
J. Med., 2010; 362: 2260–2270
  [44] Kantarjian H.M., Cortes J.E., O’Brien S., Luthra R., Giles F., Verstovsek 
S., Faderl S., Thomas D., Garcia-Manero G., Rios M.B., Shan J., 
Jones D., Talpaz M.: Long-term survival benefit and improved com-
plete cytogenetic and molecular response rates with imatinib mesylate 
in Philadelphia chromosome-positive chronic-phase chronic myeloid 
leukemia after failure of interferon-a. Blood, 2004; 104: 1979–1988
  [45] Konig H., Copland M., Chu S., Jove R., Holyoake T.L., Bhatia R.: 
Effects of dasatinib on SRC kinase activity and downstream intracel-
lular signaling in primitive chronic myelogenous leukemia hemato-
poietic cells. Cancer Res., 2008; 68: 9624–9633
  [46] Kreutzman A., Juvonen V., Kairisto V., Ekblom M., Stenke L., 
Seggewiss R., Porkka K., Mustjoki S.: Mono/oligoclonal T and NK 
cells are common in chronic myeloid leukemia patients at diagnosis 
and expand during dasatinib therapy. Blood, 2010; 116: 772–782
 [47] Kubota T.: Gastrointestinal stromal tumor (GIST) and imatinib. Int. J. 
Clin. Oncol., 2006; 11: 184–189
  [48] Larson R.A., Druker B.J., Guilhot F., O’Brien S.G., Riviere G.J., 
Krahnke T., Gathmann I., Wang Y.: Imatinib pharmacokinetics and 
its correlation with response and safety in chronic-phase chronic my-
eloid leukemia: a subanalysis of the IRIS study. Blood, 2008; 111: 
4022–4028
  [49] Mahon F.X., Hayette S., Lagarde V., Belloc F., Turcq B., Nicolini F., 
Belanger C., Manley P.W., Leroy C., Etienne G., Roche S., Pasquet 
J.M.: Evidence that resistance to nilotinib may be due to BCR-ABL, 
Pgp, or Src kinase overexpression. Cancer Res., 2008; 68: 9809–9816
  [50] Manley P.W., Cowan-Jacob S.W., Mestan J.: Advances in the structu-
ral biology, design and clinical development of Bcr-Abl kinase inhibi-
tors for the treatment of chronic myeloid leukaemia. Biochim. Biophys. 
Acta, 2005; 1754: 3–13
 [51] Manley P.W., Drueckes P., Fendrich G., Furet P., Liebetanz J., Martiny-
Baron G., Mestan J., Trappe J., Wartmann M., Fabbro D.: Extended 
kinase profile and properties of the protein kinase inhibitor nilotinib. 
Biochim. Biophys. Acta, 2010; 1804: 445–453
  [52] Mauro M.J., Druker B.J.: STI571: targeting BCR-ABL as therapy for 
CML. Oncologist, 2001; 6: 233–238
  [53] Moriggl R., Sexl V., Kenner L., Duntsch C., Stangl K., Gingras S., 
Hoffmeyer A., Bauer A., Piekorz R., Wang D., Bunting K.D., Wagner 
E.F., Sonneck K., Valent P., Ihle J.N., Beug H.: Stat5 tetramer forma-
tion is associated with leukemogenesis. Cancer Cell, 2005; 7: 87–99
 [54] Mustjoki S., Ekblom M., Arstila T.P., Dybedal I., Epling-Burnette P.K., 
Guilhot F., Hjorth-Hansen H., Höglund M., Kovanen P., Laurinolli 
T., Liesveld J., Paquette R., Pinilla-Ibarz J., Rauhala A., Shah N., 
Simonsson B., Sinisalo M., Steegmann J.L., Stenke L., Porkka K.: 
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor da-
satinib therapy. Leukemia, 2009; 23: 1398–1405
  [55] Nam S., Williams A., Vultur A., List A., Bhalla K., Smith D., Lee F.Y., 
Jove R.: Dasatinib (BMS-354825) inhibits Stat5 signaling associated 
with apoptosis in chronic myelogenous leukemia cells. Mol. Cancer 
Ther., 2007; 6: 1400–1405
  [56] O’Hare T., Shakespeare W.C., Zhu X., Eide C.A., Rivera V.M., Wang 
F., Adrian L.T., Zhou T., Huang W.S., Xu Q., Metcalf C.A. 3rd, Tyner 
J.W., Loriaux M.M., Corbin A.S., Wardwell S., Ning Y., Keats J.A., 
Wang Y., Sundaramoorthi R., Thomas M., Zhou D., Snodgrass J., 
Commodore L., Sawyer T.K., Dalgarno D.C., Deininger M.W., Druker 
B.J., Clackson T.: AP24534, a pan-BCR-ABL inhibitor for chronic my-
eloid leukemia, potently inhibits the T315I mutant and overcomes mu-
tation-based resistance. Cancer Cell, 2009; 16: 401–412
 [57] O’Hare T., Walters D.K., Stoffregen E.P., Jia T., Manley P.W., Mestan J., 
Cowan-Jacob S.W., Lee F.Y., Heinrich M.C., Deininger M.W., Druker 
B.J.: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 
against clinically relevant imatinib-resistant Abl kinase domain mu-
tants. Cancer Res., 2005; 65: 4500–4505
  [58] Olivieri A., Manzione L.: Dasatinib: a new step in molecular target 
therapy. Ann. Oncol., 2007; 18(Suppl.6): vi42–vi46
  [59] Ottmann O.G., Druker B.J., Sawyers C.L., Goldman J.M., Reiffers 
J., Silver R.T., Tura S., Fischer T., Deininger M.W., Schiffer C.A., 
Baccarani M., Gratwohl A., Hochhaus A., Hoelzer D., Fernandes-
Reese S., Gathmann I., Capdeville R., O’Brien S.G.: A phase 2 stu-
dy of imatinib in patients with relapsed or refractory Philadelphia 
chromosome-positive acute lymphoid leukemias. Blood, 2002; 100: 
1965–1971
  [60] Paquette R., Shah N., Sawyers C., Martinelli G., Nicoll J.: Pha-739358: 
a pan-aurora kinase inhibitor. Hematology Meeting Reports, 2008; 2: 
92–93
 [61] Pene-Dumitrescu T., Smithgall T.E.: Expression of a Src family kinase 
in chronic myelogenous leukemia cells induces resistance to imatinib 
in a kinase-dependent manner. J. Biol. Chem., 2010; 285: 21446–21457
  [62] Pui C.H., Jeha S.: New therapeutic strategies for the treatment of acu-
te lymphoblastic leukaemia. Nat. Rev. Drug Discov., 2007; 6: 149–165
 [63] Puttini M., Coluccia A.M., Boschelli F., Cleris L., Marchesi E., Donella-
Deana A., Ahmed S., Redaelli S., Piazza R., Magistroni V., Andreoni 
F., Scapozza L., Formelli F., Gambacorti-Passerini C.: In vitro and in 
vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-re-
sistant Bcr-Abl+ neoplastic cells. Cancer Res., 2006; 66: 11314–11322
  [64] Quintas-Cardama A., Kantarjian H., Talpaz M., O’Brien S., Garcia-
Manero G., Verstovsek S., Rios M.B., Hayes K., Glassman A., Bekele 
B.N., Zhou X., Cortes J.: Imatinib mesylate therapy may overcome the 
poor prognostic significance of deletions of derivative chromosome 
9 in patients with chronic myelogenous leukemia. Blood, 2005; 105: 
2281–2286
  [65] Radich J.P.: Philadelphia chromosome-positive acute lymphocytic leu-
kemia. Hematol. Oncol. Clin. North Am., 2001; 15: 21–36
  [66] Rajaraman S., Davis W.S., Mahakali-Zama A., Evans H.K., Russell 
L.B., Bedell M.A.: An allelic series of mutations in the Kit ligand gene 
of mice. II. Effects of ethylnitrosourea-induced Kitl point mutations 
on survival and peripheral blood cells of Kitl(Steel) mice. Genetics, 
2002; 162: 341–353
 [67] Ravandi F.: Dasatinib, an immunomodulator? Blood, 2010; 116: 673–674
  [68] Ravandi F., O’Brien S., Thomas D., Faderl S., Jones D., Garris R., 
Dara S., Jorgensen J., Kebriaei P., Champlin R., Borthakur G., Burger 
J., Ferrajoli A., Garcia-Manero G., Wierda W., Cortes J., Kantarjian 
H.: First report of phase 2 study of dasatinib with hyper-CVAD for the 
frontline treatment of patients with Philadelphia chromosome-positi-
ve (Ph+) acute lymphoblastic leukemia. Blood, 2010; 116: 2070–2077
  [69] Ray A., Cowan-Jacob S.W., Manley P.W., Mestan J., Griffin J.D.: 
Identification of BCR-ABL point mutations conferring resistance to 
the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagene-
sis study. Blood, 2007; 109: 5011–5015
Kosior K. et al. – Tyrosine kinase inhibitors in hematological malignancies
827  
       -               -               -               -               -         [70] Redaelli S., Piazza R., Rostagno R., Magistroni V., Perini P., Marega 
M., Gambacorti-Passerini C., Boschelli F.: Activity of bosutinib, da-
satinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. 
J. Clin. Oncol., 2009; 27: 469–471
  [71] Remsing Rix L.L., Rix U., Colinge J., Hantschel O., Bennett K.L., 
Stranzl T., Müller A., Baumgartner C., Valent P., Augustin M., Till 
J.H., Superti-Furga G.: Global target profile of the kinase inhibitor bo-
sutinib in primary chronic myeloid leukemia cells. Leukemia, 2009; 
23: 477–485
 [72] Rudduck-Sivaswaren C., Tien S.L., Lim P., Lim E., Lie D.K., Tan P.H., 
Lee A.S.: Evidence for deletion of 9q as a two-step process in chronic 
myeloid leukemia. Clin. Genet., 2005; 68: 461–465
  [73] Sacha T.: Molekularne mechanizmy oporności na imatinib. Acta 
Haematol. Pol., 2003; 34: 263–275
 [74] Sawyers C.L., Hochhaus A., Feldman E., Goldman J.M., Miller C.B., 
Ottmann O.G., Schiffer C.A., Talpaz M., Guilhot F., Deininger M.W., 
Fischer T., O’Brien S.G., Stone R.M., Gambacorti-Passerini C.B., 
Russell N.H., Reiffers J.J., Shea T.C., Chapuis B., Coutre S., Tura S., 
Morra E., Larson R.A., Saven A., Peschel C., Gratwohl A., Mandelli 
F., Ben-Am M., Gathmann I., Capdeville R., Paquette R.L., Druker 
B.J.: Imatinib induces hematologic and cytogenetic responses in pa-
tients with chronic myelogenous leukemia in myeloid blast crisis: re-
sults of a phase II study. Blood, 2002; 99: 3530–3539
 [75] Schade A.E., Schieven G.L., Townsend R., Jankowska A.M., Susulic 
V., Zhang R., Szpurka H., Maciejewski J.P.: Dasatinib, a small-mo-
lecule protein tyrosine kinase inhibitor, inhibits T-cell activation and 
proliferation. Blood, 2008; 111: 1366–1377
 [76] Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan 
J., Sawyers C.L.: Multiple BCR-ABL kinase domain mutations confer 
polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) 
in chronic phase and blast crisis chronic myeloid leukemia. Cancer 
Cell, 2002; 2: 117–125
  [77] Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., Sawyers C.L.: 
Overriding imatinib resistance with a novel ABL kinase inhibitor. 
Science, 2004; 305: 399–401
  [78] Si J., Collins S.J.: Activated Ca2+/calmodulin-dependent protein ki-
nase IIg is a critical regulator of myeloid leukemia cell proliferation. 
Cancer Res., 2008; 68: 3733–3742
  [79] Soverini S., Colarossi S., Gnani A., Rosti G., Castagnetti F., Poerio 
A., Iacobucci I., Amabile M., Abruzzese E., Orlandi E., Radaelli F., 
Ciccone F., Tiribelli M., di Lorenzo R., Caracciolo C., Izzo B., Pane 
F., Saglio G., Baccarani M., Martinelli G.: Contribution of ABL ki-
nase domain mutations to imatinib resistance in different subsets of 
Philadelphia-positive patients: by the GIMEMA Working Party on 
Chronic Myeloid Leukemia. Clin. Cancer Res., 2006; 12: 7374–7379
  [80] Steinberg M.: Dasatinib: a tyrosine kinase inhibitor for the treatment 
of chronic myelogenous leukemia and Philadelphia chromosome-po-
sitive acute lymphoblastic leukemia. Clin. Ther., 2007; 29: 2289–2308
  [81] Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette 
R., Cortes J., O’Brien S., Nicaise C., Bleickardt E., Blackwood-
Chirchir M.A., Iyer V., Chen T.T., Huang F., Decillis A.P., Sawyers 
C.L.: Dasatinib in imatinib-resistant Philadelphia chromosome-posi-
tive leukemias. N. Engl. J. Med., 2006; 354: 2531–2541
  [82] Talpaz M., Silver R.T., Druker B.J., Goldman J.M., Gambacorti-
Passerini C., Guilhot F., Schiffer C.A., Fischer T., Deininger M.W., 
Lennard A.L., Hochhaus A., Ottmann O.G., Gratwohl A., Baccarani 
M., Stone R., Tura S., Mahon F.X., Fernandes-Reese S., Gathmann 
I., Capdeville R., Kantarjian H.M., Sawyers C.L.: Imatinib induces 
durable hematologic and cytogenetic responses in patients with ac-
celerated phase chronic myeloid leukemia: results of a phase 2 study. 
Blood, 2002; 99: 1928–1937
  [83] Tokarski J.S., Newitt J.A., Chang C.Y., Cheng J.D., Wittekind M., 
Kiefer S.E., Kish K., Lee F.Y., Borzillerri R., Lombardo L.J., Xie D., 
Zhang Y., Klei H.E.: The structure of Dasatinib (BMS-354825) bo-
und to activated ABL kinase domain elucidates its inhibitory activi-
ty against imatinib-resistant ABL mutants. Cancer Res., 2006; 66: 
5790–5797
  [84] Tsao A.S., Kantarjian H., Cortes J., O’Brien S., Talpaz M.: Imatinib 
mesylate causes hypopigmentation in the skin. Cancer, 2003; 98: 
2483–2487
  [85] Wadleigh M., DeAngelo D.J., Griffin J.D., Stone R.M.: After chronic 
myelogenous leukemia: tyrosine kinase inhibitors in other hematolo-
gic malignancies. Blood, 2005; 105: 22–30
  [86] Wassmann B., Pfeifer H., Scheuring U.J., Binckebanck A., Gökbuget 
N., Atta J., Brück P., Rieder H., Schoch C., Leimer L., Schwerdtfeger 
R., Ehninger G., Lipp T., Perz J., Stelljes M., Gschaidmeier H., Hoelzer 
D., Ottmann O.G.: Early prediction of response in patients with re-
lapsed or refractory Philadelphia chromosome-positive acute lympho-
blastic leukemia (Ph+ALL) treated with imatinib. Blood, 2004; 103: 
1495–1498
  [87] Wei G., Rafiyath S., Liu D.: First-line treatment for chronic myeloid 
leukemia: dasatinib, nilotinib, or imatinib. J. Hematol. Oncol., 2010; 
3: 47
  [88] Weisberg E., Manley P.W., Breitenstein W., Brüggen J., Cowan-Jacob 
S.W., Ray A., Huntly B., Fabbro D., Fendrich G., Hall-Meyers E., 
Kung A.L., Mestan J., Daley G.Q., Callahan L., Catley L., Cavazza 
C., Azam M., Neuberg D., Wright R.D., Gilliland D.G., Griffin J.D.: 
Characterization of AMN107, a selective inhibitor of native and mu-
tant Bcr-Abl. Cancer Cell, 2005; 7: 129–141
  [89] White D.L., Saunders V.A., Dang P., Engler J., Venables A., Zrim S., 
Zannettino A., Lynch K., Manley P.W., Hughes T.: Most CML patients 
who have a suboptimal response to imatinib have low OCT-1 activi-
ty: higher doses of imatinib may overcome the negative impact of low 
OCT-1 activity. Blood, 2007; 110: 4064–4072
  [90] Wilson M.B., Schreiner S.J., Choi H.J., Kamens J., Smithgall T.E.: 
Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for 
Src family kinases in Bcr-Abl signal transduction and oncogenesis. 
Oncogene, 2002; 21: 8075–8088
 [91] Wisniewski D., Lambek C.L., Liu C., Strife A., Veach D.R., Nagar B., 
Young M.A., Schindler T., Bornmann W.G., Bertino J.R., Kuriyan J., 
Clarkson B.: Characterization of potent inhibitors of the Bcr-Abl and 
the c-kit receptor tyrosine kinases. Cancer Res., 2002; 62: 4244–4255
  [92] Wolff N.C., Veach D.R., Tong W.P., Bornmann W.G., Clarkson B., 
Ilaria R.L.Jr: PD166326, a novel tyrosine kinase inhibitor, has gre-
ater antileukemic activity than imatinib mesylate in a murine model 
of chronic myeloid leukemia. Blood, 2005; 105: 3995–4003
  [93] Wu J., Meng F., Lu H., Kong L., Bornmann W., Peng Z., Talpaz M., 
Donato N.J.: Lyn regulates BCR-ABL and Gab2 tyrosine phosphory-
lation and c-Cbl protein stability in imatinib-resistant chronic myelo-
genous leukemia cells. Blood, 2008; 111: 3821–3829
  [94] Yu H., Jove R.: The STATs of cancer-new molecular targets come of 
age. Nat. Rev. Cancer, 2004; 4: 97–105
The authors have no potential conflicts of interest to declare.
Postepy Hig Med Dosw (online), 2011; tom 65: 819-828
828 
       -               -               -               -               -       